Shionogi & Co., Ltd. (TYO:4507)

Japan flag Japan · Delayed Price · Currency is JPY
2,647.00
+48.50 (1.87%)
Sep 5, 2025, 10:45 AM JST
1.87%
Market Cap2.21T
Revenue (ttm)440.50B
Net Income (ttm)179.12B
Shares Out850.98M
EPS (ttm)210.53
PE Ratio12.34
Forward PE12.18
Dividend66.00 (2.55%)
Ex-Dividend DateSep 29, 2025
Volume614,200
Average Volume2,063,050
Open2,597.00
Previous Close2,598.50
Day's Range2,595.00 - 2,653.50
52-Week Range2,028.50 - 2,724.00
Beta0.14
RSI54.58
Earnings DateOct 27, 2025

About Shionogi &

Shionogi & Co., Ltd. researches, develops, manufactures, and distributes pharmaceuticals, diagnostic reagents, and medical devices. It offers and develops drugs in the areas of infectious diseases, COVID-19, tumors, sclerosis, pomp, fragile X syndrome, and other diseases. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan. [Read more]

Sector Healthcare
Founded 1878
Employees 4,955
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4507
Full Company Profile

Financial Performance

In 2024, Shionogi &'s revenue was 438.27 billion, an increase of 0.73% compared to the previous year's 435.08 billion. Earnings were 170.44 billion, an increase of 5.19%.

Financial Statements

News

Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2025 Earnings Conference Call July 28, 2025 3:30 AM ET Company Participants John A.

5 weeks ago - Seeking Alpha

Shionogi & Co. reports Q1 results

5 weeks ago - Seeking Alpha

Shionogi and Jordan's Guardian Angels Announce First-Ever Human Drug Study for Jordan's Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder

Large-Scale Research and Grassroots Patient Advocacy Collaborations Led to Historic Milestone for Rare Disease Community Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshir...

7 months ago - Benzinga

Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOY) Q3 2024 Earnings Conference Call January 31, 2025 3:30 AM ETCompany ParticipantsYoshimasa Kyokawa - VP, Corporate...

7 months ago - Seeking Alpha

Shionogi & Co. reports 9M results

7 months ago - Seeking Alpha

Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOY) Q2 2024 Earnings Call Transcript October 29, 2024 2:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Isao Teshirogi - Chair...

11 months ago - Seeking Alpha

Antibiotics, an important but tricky business, says Shionogi CEO [Advocacy Lab Content]

Producing antibiotics remains imperative but production is hindered by an unattractive business model, says Shionogi CEO. Pull incentives are needed to ensure safe, global supplies of vital drugs.

1 year ago - EURACTIV.com

Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2024 Earnings Conference Call July 29, 2024 4:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Masako Kudou - Vice Presi...

1 year ago - Seeking Alpha

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease

OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and Maze Therapeutic...

1 year ago - Business Wire

Shionogi & Co., Ltd. (SGIOF) Q2 2023 Earnings Conference Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q2 2023 Earnings Conference Call October 31, 2023 9:30 PM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Isao Teshirogi - Representative Di...

2 years ago - Seeking Alpha

Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q1 2023 Earnings Conference Call July 31, 2023 5:15 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications John Keller - Senior Executive Office...

2 years ago - Seeking Alpha

Shionogi: Likely The Last Viable COVID Play

Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside.

2 years ago - Seeking Alpha

Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q3 2022 Earnings Conference Call January 30, 2023 1:00 AM ET Company Participants Yoshimasa Kyokawa - Investor Relations Masako Kudou - Vice President, Finance and A...

2 years ago - Seeking Alpha